" class="no-js "lang="en-US"> Sumitomo Dainippon Pharma Co. - Medtech Alert
Saturday, July 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Sumitomo Dainippon Pharma Co. | Pharmtech Focus

Sumitomo Dainippon Pharma Co.

About Sumitomo Dainippon Pharma Co.

Sumitomo Dainippon Pharma Co.

Sumitomo Dainippon Pharma Co., Ltd. is a pharmaceutical company based in Japan. Its headquarters are in Chuo-ku, Osaka. The original Dainippon Pharmaceuticals was established in 1885 by Nagayo Sensai, a graduate of Tekijuku – the first private medical school in Japan established by Ogata Kōan.

Related Story

Diseases

 Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage | MTA

Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage

May 16 2023

Exscientia today announced that Sumitomo Pharma plans to initiate a Phase 1 clinical study of […]

Clinical Trials

 Exscientia Announces Second Molecule Created Using AI from Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial | Pharmtech Focus

Exscientia Announces Second Molecule Created Using AI from Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial

May 13 2021

Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) is pleased to acknowledge that Sumitomo Dainippon Pharma Co., […]